June 19, 2017
Novartis’s division wins EC approval for its cancer drug
European Commission (EC) has approved Sandoz’s Rixathon (biosimilar rituximab) for use in all indications of the reference medicine, MabThera.
Pharmaceuticals, Biotechnology and Life Sciences
European Commission (EC) has approved Sandoz’s Rixathon (biosimilar rituximab) for use in all indications of the reference medicine, MabThera.